Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod

Recruiting now · Phase 4

Conditions studied: HSIL, High-Grade Squamous Intraepithelial Lesions, Vaginal Microbiome, Biomarkers

In brief

The goal of this clinical trial is to identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. Participants will be divided in 3 groups: CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week and will be treated with LEEP procedure; 2) patients with CIN 3 who will undergo standard treatment with LEEP procedure; 3) patients with negative cytology and HPV (human papillomavirus) test. Blood and cervicovaginal lavage collections will be performed at different times, for comparisons between cellular response profiles to imiquimod during treatment and baseline levels in healthy patients.

Key facts

Study ID
NCT06356012
Run by
Barretos Cancer Hospital
People needed
96
Starts
2024-04-02
Expected to finish
2028-12-31
Last updated by the study team
2025-02-05

Who can join

Age: 25 and older, up to 45. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.